文献速递前列腺癌

转移性去势抵抗性前列腺癌中PSA未升高但影像学进展:PREVAIL研究的事后分析

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-01-24

该事后分析纳入PREVAIL研究中接受恩扎卢胺治疗的872例化疗初治无症状或轻微症状的转移性去势抵抗性前列腺癌(mCRPC)患者,分析影像学进展时PSA升高(>1.05倍3个月前PSA)与未升高(≤1.05倍)两组的临床特征与结局。结果显示,可评估PSA的265例影像学进展患者中近四分之一PSA未升高,该组中位无进展生存期8.3个月 vs 升高组11.1个月(HR 1.68;95%CI 1.26-2.23),总生存两组相似。

要点

  • 恩扎卢胺治疗中影像学进展时PSA未升高是常见现象,265例中近四分之一。
  • PSA未升高组中位无进展生存期8.3个月 vs 升高组11.1个月(HR 1.68;95%CI 1.26-2.23)。
  • 总生存两组相似,但两组24个月时仍处于风险中的患者均不足一半。

核心结论

  • 恩扎卢胺治疗的mCRPC患者中,影像学进展时PSA未升高是常见现象。
  • 由于晚期前列腺癌再分期常由PSA升高引导,结果表明恩扎卢胺治疗中疾病进展可不伴PSA升高。
  • 包含不完全依赖系列血清PSA测定的影像学的疾病监测策略可能更准确地识别疾病进展。

研究设计与样本

  • PREVAIL研究的事后分析,纳入化疗初治无症状或轻微症状的mCRPC男性872例,接受雄激素受体抑制剂恩扎卢胺治疗。
  • 在影像学进展时按PSA升高(>1.05倍3个月前PSA)与未升高(≤1.05倍)分组,比较临床特征与疾病结局。

主要发现

  • 恩扎卢胺组265例影像学进展且PSA可评估的患者中,近四分之一PSA未升高。
  • PSA未升高组中位无进展生存期8.3个月 vs PSA升高组11.1个月(HR 1.68;95%CI 1.26-2.23)。
  • 总生存两组相似,但两组24个月时仍处于风险中的患者均不足一半。
  • 两组基线临床特征相似。

关键数值与推荐

  • PSA升高定义为>1.05倍3个月前PSA水平,PSA未升高定义为≤1.05倍3个月前PSA水平。

临床怎么用

  • 作者认为,包含不完全依赖系列血清PSA测定的影像学的疾病监测策略可能更准确地识别疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced prostate cancer is a phenotypically diverse disease that evolves through multiple clinical courses. PSA level is the most widely used parameter for disease monitoring, but it has well-recognized limitations. Unlike in clinical trials, in practice, clinicians may rely on PSA monitoring alone to determine disease status on therapy. This approach has not been adequately tested. METHODS: Chemotherapy-naive asymptomatic or mildly symptomatic men (n=872) with metastatic castration-resistant prostate cancer (mCRPC) who were treated with the androgen receptor inhibitor enzalutamide in the PREVAIL study were analyzed post hoc for rising versus nonrising PSA (empirically defined as >1.05 vs ⩽1.05 times the PSA level from 3 months earlier) at the time of radiographic progression. Clinical characteristics and disease outcomes were compared between the rising and nonrising PSA groups. RESULTS: Of 265 PREVAIL patients with radiographic progression and evaluable PSA levels on the enzalutamide arm, nearly one-quarter had a nonrising PSA. Median progression-free survival in this cohort was 8.3 months versus 11.1 months in the rising PSA cohort (hazard ratio 1.68; 95% confidence interval 1.26-2.23); overall survival was similar between the two groups, although less than half of patients in either group were still at risk at 24 months. Baseline clinical characteristics of the two groups were similar. CONCLUSIONS: Non-rising PSA at radiographic progression is a common phenomenon in mCRPC patients treated with enzalutamide. As restaging in advanced prostate cancer patients is often guided by increases in PSA levels, our results demonstrate that disease progression on enzalutamide can occur without rising PSA levels. Therefore, a disease monitoring strategy that includes imaging not entirely reliant on serial serum PSA measurement may more accurately identify disease progression.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bryce AH, Alumkal JJ, Armstrong A, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017. PMID: 28117385. doi:10.1038/pcan.2016.71

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。